BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zyga Technology, Inc. Announces $25 Million Venture Financing


5/17/2012 6:38:56 AM

MINNEAPOLIS, May 16, 2012 /PRNewswire/ -- Zyga Technology announced today that it had raised $25 million in a Series C financing led by new investor Versant Ventures of Menlo Park, California. Joining Versant in this round are existing investors Split Rock Partners, Domain Associates, and MB Venture Partners. With this investment, Kirk Nielsen, Managing Director, Versant Ventures will join the board of directors of Zyga.

(Logo: http://photos.prnewswire.com/prnh/20110118/CG30384LOGO)

"We are thrilled to have the support of Versant in this critical round of financing. Having Kirk on our board will provide us with additional guidance as we navigate both the commercial strategy for our SImmetry® Sacroiliac Joint Fusion System(TM) and the rigors of clinical trials for the GLYDER(TM) facet resurfacing product," said Jim Bullock, President and Chief Executive Officer. SImmetry, a device designed to treat low back pain emanating from the sacroiliac joint, has been approved by the FDA for commercialization. "These funds will allow us to focus on building world class sales, marketing, and clinical efforts to commercialize this important new technology," said Bullock. "Additionally, I am very encouraged with the preliminary European clinical trial results of Glyder, our facet resurfacing device. This funding will help expand our clinical efforts which will ultimately serve to gain CE Mark and US trial approval," concluded Bullock.

About Zyga Technology

Based in Minneapolis, MN, Zyga Technology was founded to develop and market innovative, minimally invasive surgical solutions to treat conditions of the spine. Zyga has put together a team of engineers, marketing personnel, and management with significant experience developing medical devices for the spine industry.

Press Contact:

Paul Hess

Senior Marketing Manager

Zyga Technology, Inc.

(612) 455-1061

phess@zygatech.com




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES